Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
An update from Takeda Pharmaceutical Co ( (JP:4502) ) is now available.
Takeda Pharmaceutical Co has presented promising data from its Phase 3 clinical trials of oveporexton (TAK-861), an investigational oral orexin receptor 2 agonist, at the World Sleep 2025 Congress. The studies demonstrated statistically significant improvements in narcolepsy type 1 symptoms, with no serious treatment-related adverse events reported, marking a potential breakthrough in addressing the underlying cause of this chronic neurological disease.
The most recent analyst rating on (JP:4502) stock is a Hold with a Yen4693.00 price target. To see the full list of analyst forecasts on Takeda Pharmaceutical Co stock, see the JP:4502 Stock Forecast page.
More about Takeda Pharmaceutical Co
Takeda Pharmaceutical Co is a leading global biopharmaceutical company based in Japan, focusing on innovative medicines in areas such as oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies. The company is recognized for its leadership in orexin science, particularly in developing treatments for narcolepsy type 1.
YTD Price Performance: 11.80%
Average Trading Volume: 4,216,741
Technical Sentiment Signal: Buy
Current Market Cap: Yen7249.6B
For detailed information about 4502 stock, go to TipRanks’ Stock Analysis page.